Effective 7/24/2026: Texas Medicaid Preferred Drug List Updates

Date: 07/23/26

Effective July 24, 2026, certain medications will move from Preferred Drug List (PDL) to Non-Preferred Drugs (NPD) status and may require prior authorization or use of a preferred alternative.

Not Reviewed (NR) status means a medication is not currently classified as either PDL or NPD. As part of this update, some NR medications will be reclassified as NPDs. Medications designated as NPDs will require prior authorization, including a review of available preferred alternatives and applicable clinical criteria before coverage can be approved.

Providers should review the updated Texas Health and Human Services Commission (HHSC) Texas Medicaid Preferred Drug webpage and applicable prior authorization criteria before prescribing or continuing medications affected by the July 2026 update.

The table below summaries some of the anticipated changes from the most recent updates of the PDL:

Drug/Class	Product	Change
Movement Disorders	Austedo XR tablets	PDL updated to NPD
	Austedo XR Titration Pack	PDL updated to NPD
	Ingrezza Initiation Pack	PDL updated to NPD
	Ingrezza Sprinkle capsules	PDL updated to NPD
	Xenazine tablets	PDL updated to NPD
Lipotropics, Other	Tricor tablets	PDL updated to NPD
	Trilipix capsules DR	PDL updated to NPD
PAH Agents, Oral and Inhaled	Letairis tablets	PDL updated to NPD
Hereditary Angioedema Treatments	Sajazir syringe	PDL updated to NPD
Phosphate Binders	Renvela tablets	PDL updated to NPD
ARB/neprilysin inhibitor combinations	Entresto tablets	PDL updated to NPD
Cytokine and CAM antagonist	Otezla XR tablets	NR updated to NPD
Immunomodulators, atopic dermatitis	Zoryve cream 0.05%	NR updated to  NPD
	Anzupgo cream	NR updated to NPD

If you have any questions or need more information please call Pharmacy Services at 1-866-768-7147.